TIDMHCM

Hutchison China Meditech Limited

30 October 2020

Press Release

Chi-Med to Attend Upcoming Industry and Investor Virtual Conferences

Hong Kong, Shanghai, & Florham Park, NJ: Friday, October 30, 2020: Hutchison China MediTech Limited (" Chi-Med ") (Nasdaq/AIM: HCM) today announces that Mr. Christian Hogg, Chief Executive Officer of Chi-Med, will present or participate in the following virtual conferences:

   --      The 15(th) Citi China Investor Conference on Thursday, November 5, 2020; and

-- The "China Summit Survey Results: Where is the "Bridge to Innovation" Headed?" Panel as part of the BioCentury-BayHelix 7(th) China Healthcare Summit on Monday, November 9, 2020.

Members of the management team will attend the above conferences in one-on-one meetings, and will also attend the following virtual investor conferences at certain times:

   --      The Bank of America 2020 China Conference held from November 2 to 13, 2020; 
   --      The Goldman Sachs Asia Pacific Healthcare Forum held from November 16 to 18, 2020; 
   --      The 11(th) Annual Jefferies Global Healthcare Conference held from November 17 to 19, 2020; 
   --      The Morgan Stanley Asia Pacific Summit held from November 18 to 20, 2020; and 
   --      The Piper Sandler 32(nd) Annual Healthcare Conference held from December 1 to 3, 2020.

Further information are available at www.chi-med.com in the Shareholder Information section under " Events, Circulars & Forms ."

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com .

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President                            +852 2121 8200 
  Annie Cheng, Vice President                                +1 (973) 567 3786 
 
Media Enquiries 
  Americas - Brad Miles, Solebury Trout                      +1 (917) 570 7340 (Mobile) 
                                                              bmiles@troutgroup.com 
  Europe - Ben Atwell / Alex Shaw, FTI Consulting            +44 20 3727 1030 / +44 7771 913 902 (Mobile) / 
                                                              +44 7779 545 055 (Mobile) 
                                                              Chi-Med@fticonsulting.com 
  Asia - Joseph Chi Lo / Zhou Yi, Brunswick                  +852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 97 
                                                             83 6894 (Mobile), y zhou@brunswickgroup.com 
 
Nominated Advisor 
  Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) 
   Limited                                                   +44 (20) 7886 2500

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAWPGUCUUPUGGU

(END) Dow Jones Newswires

October 30, 2020 08:00 ET (12:00 GMT)

Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Hutchison China Meditech Charts.
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Hutchison China Meditech Charts.